PBR reports that British-Swedish giant AstraZeneca has entered into a new deal with generic producer Torrent Pharmaceuticals to brand and market 18 of its products in 9 emerging markets. This is AZ's first foray into the generics arena.
In a statement, AstraZeneca said: "Emerging markets are forecast to contribute around 70% of pharmaceutical industry growth in the next five years, and branded generics represent approximately 50% by value in these emerging markets. AstraZeneca believes it can capitalize on this opportunity and over time plans to broaden its portfolio beyond these initial 18 products."
The deal underscores how MNC drug makers are looking to broaden their footprints in emerging countries as a host of their most lucrative medicines lose patent protection.
Patents on seven AstraZeneca drugs will expire in the next four years. They will include its three biggest sellers: Nexium, an ulcer treatment; Seroquel, an anti-psychotic; and Crestor, an anti-cholesterol drug.
Wow - my blood pressure is up, my stomach hurts and I'm feeling a little crazy.
Posted by Bruce Lehr March 11th 2010.
Comments